Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Alan Van Goethem

Awards & Distinctions

33 Results

2023

Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation

Alan Van GoethemJill DeleuNurten YigitCeline EveraertMyrthala Moreno-SmithSanjeev A VasudevanFjoralba ZekaFleur DemuynckEveline BarbieriFranki Speleman et al.

A2 Journal Article in NAR CANCER

2018

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

Fjoralba ZekaAnneleen DecockAlan Van GoethemKatrien VanderheydenFleur DemuynckTim LammensHetty HelsmoortelJoëlle VermeulenRosa NogueraAna P. Berbegall et al.

A1 Journal Article in JCI INSIGHT

Circulating microRNA biomarkers for metastatic neuroblastoma

Fjoralba ZekaAlan Van GoethemTim LammensAnneleen DecockHetty HelsmoortelGenevieve LaureysMichael HogartyEveline BarbieriJason ShohetFrank Berthold et al.

Longitudinal evaluation of murine serum microRNAs as biomarkers for neuroblastoma burden and therapeutic TP53 reactivation

Alan Van GoethemNurten YigitCeline EveraertMyrthala Moreno-SmithSanjeev A VasudevanFjoralba ZekaFleur DemunckEveline BarbieriFranki SpelemanPieter Mestdagh et al.

Pharmacological restoration of tumour suppressor protein p53 in neuroblastoma : seeking synergy and non-invasive biomarkers

Alan Van GoethemJo VandesompeleTom Van Maerken

A2 Journal Article in BELGIAN JOURNAL OF MEDICAL ONCOLOGY

2017

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Alan Van GoethemNurten YigitMyrthala Moreno-SmithSanjeev A VasudevanEveline BarbieriFranki SpelemanJason ShohetJo VandesompeleTom Van Maerken

A1 Journal Article in ONCOTARGET

EV-TRACK : transparent reporting and centralizing knowledge in extracellular vesicle research

Jan Van DeunPieter MestdaghPatrizia AgostinisÖzden AkaySushma AnandJasper AnckaertZoraida Andreu MartinezTine BaetensEls BegheinLaurence Bertier et al.

A1 Journal Article in NATURE METHODS

MicroRNA expression analysis using small RNA sequencing discovery and RT-qPCR-based validation

Alan Van GoethemPieter MestdaghTom Van MaerkenJo Vandesompele

Bookchapter in Functional genomics : methods and protocols

Restoration of p53 in neuroblastoma : seeking synergy and non-invasive biomakers

Alan Van GoethemTom Van MaerkenJo Vandesompele

2016

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples

Alan Van GoethemNurten YigitCeline EveraertMyrthala Moreno-SmithLiselot MusEveline BarbieriFranki SpelemanPieter MestdaghJason ShohetTom Van Maerken et al.

A1 Journal Article in SCIENTIFIC REPORTS

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

Dual targeting of ALK and RET: establishing a novel basis for the treatment of neuroblastoma

Liselot MusShana ClaeysBram De WildeGenevieve LaureysAlan Van GoethemJohannes SchulteKatleen De PreterIrina LambertzFranki Speleman

Identification of non-invasive biomarkers for treatment response in neuroblastoma by circulating miRNA profiling

Alan Van GoethemNurten YigitMythala Moreno-SmithCeline EveraertOlivier DelattrePieter MestdaghSaurabh AgarwalEveline BarbieriIsabelle Janoueix-LeroseyJason Shohet et al.

The HBP1 tumor suppressor is an epigenetic regulator of MYCN driven neuroblastoma through interaction with the PRC2 complex

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste Demoulin et al.

2015

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma

Ali RihaniAlan Van GoethemMaté OngenaertSara De BrouwerPieter-Jan VoldersSaurabh AgarwalKatleen De PreterPieter MestdaghJason ShohetFranki Speleman et al.

A1 Journal Article in SCIENTIFIC REPORTS

HBP1 downregulation through mutant ALK represents a novel mechanism for cooperative MYCN activation in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemCandy KumpsSara De BrouwerAnnelies FieuwTom Van MaerkenKristina AlthoffJohannes SchulteJean-Baptiste Demoulin et al.

Synergistic combined molecular treatment targeting the HBP1 tumor suppressor gene in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

The HBP1 tumour suppressor at multiple regulatory cross roads in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel R CarterAlex CazesBelamy B CheungMarilena De Mariano et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

lncRNAs as upstream regulators and downstream effectors of TP53 in neuroblastoma

Dries RombautSteve LefeverPieter-Jan VoldersJan KosterSven LindnerJohannes SchulteAlan Van GoethemRogier VersteegPeter van SluisJo Vandesompele et al.

2014

Characterization of ALK driven molecular networks identifies perturbed RET and cholinergic signaling in neuroblastoma

Irina LambertzCandy KumpsShana ClaeysSven LindlerAnneleen BeckersEls JanssensMarilena De MarianoSara De BrouwerJay GibbonsGenevieve Laureys et al.

Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma

Alan Van GoethemGwen NicholsFranki SpelemanJo VandesompeleTom Van Maerken

Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma

Alan Van GoethemGwen NicholsFranki SpelemanJo VandesompeleTom Van Maerken

Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma

Alan Van GoethemGwen NicholsFranki SpelemanJo VandesompeleTom Van Maerken

Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma

Alan Van GoethemGwen NicholsFranki SpelemanJo VandesompeleTom Van Maerken

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

Tom Van MaerkenAli RihaniAlan Van GoethemAnne De PaepeFranki SpelemanJo Vandesompele

A1 Journal Article in CANCER LETTERS

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes Schulte et al.

The HBP1 tumor suppressor is a druggable ALK downregulated gene controlling MYCN activity

Shana ClaeysCandy KumpsIrina LambertzSara De BrouwerSven LindnerAlan Van GoethemTom Van MaerkenJorge VialardJan CoolsJohannes Schulte et al.

miRBase Tracker : keeping track of microRNA annotation changes

Gert Van PeerSteve LefeverJasper AnckaertAnneleen BeckersAli RihaniAlan Van GoethemPieter-Jan VoldersFjoralba ZekaMaté OngenaertPieter Mestdagh et al.

A1 Journal Article in DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION

2013

Selective inhibition of the p53–MDM2 interaction by nutlin drugs: a new therapeutic perspective for neuroblastoma

Tom Van MaerkenAli RihaniAlan Van GoethemAnne De PaepeFranki SpelemanJo Vandesompele

A2 Journal Article in PROCEEDINGS OF THE BELGIAN ROYAL ACADEMIES OF MEDICINE